Non-Muscle Bladder Cancer in Singapore

Non-muscle invasive bladder cancer treatment encompasses a multi-modal approach designed to remove cancerous growths from the bladder’s inner lining while preventing recurrence and progression. The primary treatment involves transurethral resection of bladder tumour (TURBT), a minimally invasive procedure that removes visible tumours through the urethra without external incisions. This initial intervention serves both diagnostic and therapeutic purposes, allowing complete tumour removal while providing tissue for accurate staging and grading.

Following initial tumour removal, treatment often includes intravesical therapy – medications delivered directly into the bladder to eliminate remaining cancer cells and reduce recurrence risk. The specific treatment protocol depends on the cancer’s stage (Ta, T1, or Tis/carcinoma in situ) and grade (low or high). NMIBC treatment requires long-term commitment, as the condition tends to recur, necessitating regular surveillance and potential additional interventions. Consulting a bladder specialist in Singapore supports comprehensive treatment planning aimed at eliminating cancer, preventing progression to muscle-invasive disease, and preserving bladder function when possible.

Ideal Candidates

• Patients diagnosed with Ta or T1 bladder tumours confined to the urothelium or lamina propria
• Individuals with carcinoma in situ (CIS) detected through cystoscopy or biopsy
• Patients with adequate bladder capacity and function for intravesical therapy
• Those physically fit enough to undergo general or regional anaesthesia for TURBT
• Individuals committed to long-term surveillance and follow-up protocols
• Patients with good overall health status allowing for potential multiple procedures
• Non-smokers or those willing to quit smoking to improve treatment outcomes

Contraindications

• Active urinary tract infection requiring treatment before proceeding
• Severe bladder inflammation or reduced bladder capacity affecting treatment delivery
• Blood clotting disorders requiring careful management during surgical intervention
• Immunosuppression that may affect BCG therapy eligibility
• Pregnancy, which contraindicates certain intravesical treatments
• Previous pelvic radiation potentially affecting bladder tissue integrity
• Allergy or previous severe reaction to planned intravesical agents

The determination of treatment suitability requires comprehensive evaluation by an MOH-accredited urologist in Singapore. Individual factors such as tumour characteristics, medical history, and personal preferences all influence the treatment approach. Some patients initially deemed unsuitable for certain treatments may become candidates after addressing underlying conditions.

Transurethral Resection of Bladder Tumour (TURBT)

TURBT serves as the cornerstone of NMIBC treatment, providing both diagnosis and initial therapy. The procedure utilises a resectoscope inserted through the urethra to visualise and remove bladder tumours. Standard monopolar or bipolar electrocautery allows precise tumour removal while controlling bleeding. The surgeon systematically removes all visible tumours, including a margin of apparently normal tissue and muscle layer for accurate staging. Complete resection remains crucial for reducing recurrence risk and improving outcomes.

Enhanced Cystoscopy Techniques

Blue light cystoscopy with hexaminolevulinate (HAL) or 5-aminolevulinic acid (5-ALA) improves tumour detection compared to standard white light cystoscopy. These photodynamic agents accumulate preferentially in cancer cells, causing them to fluoresce under blue light illumination. This enhanced visualisation helps identify flat lesions like carcinoma in situ and ensures more complete tumour removal. Narrow band imaging (NBI) represents another optical enhancement technique that improves tumour detection without requiring instillation of contrast agents.

Intravesical Therapy Options

Intravesical BCG (Bacillus Calmette-Guérin) immunotherapy remains the standard treatment for high-risk NMIBC. This attenuated tuberculosis vaccine stimulates local immune response against cancer cells. Mitomycin C provides an alternative chemotherapy option, particularly for intermediate-risk disease or BCG-intolerant patients. Gemcitabine, docetaxel, and valrubicin offer additional options for specific clinical scenarios. The choice of intravesical agent depends on tumour risk stratification and patient factors.

Pre-Treatment Preparation

Before TURBT, patients undergo comprehensive evaluation including blood tests, urine analysis, and imaging studies if indicated. Anticoagulation medications typically require temporary discontinuation under medical guidance. Patients receive instructions about fasting requirements, usually nothing by mouth after midnight before the procedure. Pre-operative antibiotics may be administered to prevent infection. Anaesthesia consultation ensures safe sedation planning based on individual health status.

During the Procedure

TURBT typically takes 30-60 minutes under general or spinal anaesthesia. The urologist inserts the resectoscope through the urethra to access the bladder. Systematic bladder inspection identifies all tumour locations. Using electrocautery loops, the surgeon removes tumours in layers, ensuring adequate depth for proper staging. Cauterisation controls bleeding from resection sites. Selected areas undergo biopsy for mapping disease extent. A catheter placement allows bladder drainage and irrigation post-procedure.

For intravesical therapy, the process involves catheter insertion for medication instillation. Patients retain the solution for specified durations, typically one to two hours for BCG or chemotherapy. Position changes during retention ensure medication contact with all bladder surfaces.

Immediate Post-Treatment

Following TURBT, patients recover in a monitored setting until anaesthesia effects resolve. Continuous bladder irrigation through the catheter prevents blood clot formation. Mild bladder spasms and discomfort are managed with appropriate medications. Most patients remain hospitalised for 1-2 days depending on resection extent. Catheter removal occurs once urine clears sufficiently. Discharge instructions cover activity restrictions, warning signs, and follow-up arrangements.

First 24-48 Hours

Initial recovery focuses on monitoring for bleeding and ensuring adequate urine output. Patients should expect blood-tinged urine that gradually clears. Increased fluid intake helps flush the bladder and prevent clot formation. Pain typically remains mild, manageable with oral analgesics. Activity should be limited to gentle walking and rest. Warning signs requiring immediate medical attention include heavy bleeding, inability to urinate, fever, or severe pain.

First Week

During the first week, patients gradually resume normal activities while avoiding strenuous exercise and heavy lifting. Mild urinary symptoms including frequency, urgency, and slight burning may persist. Continued hydration remains important for healing. Sexual activity should be avoided until cleared by the urologist. Pathology results typically become available, determining the need for additional treatment. Follow-up appointments assess healing progress and discuss further management plans.

Long-term Recovery

Complete healing from TURBT occurs within 4-6 weeks. Patients beginning intravesical therapy follow specific protocols, typically weekly installations for six weeks (induction), followed by maintenance schedules. BCG therapy may cause flu-like symptoms lasting 24-48 hours post-treatment. Regular surveillance cystoscopy begins three months after initial treatment, with frequency determined by risk stratification. Lifestyle modifications including smoking cessation and dietary changes support long-term outcomes.

Effective NMIBC treatment offers significant benefits for patient outcomes and quality of life. Bladder preservation remains achievable for most patients, avoiding the need for radical cystectomy and maintaining normal urinary function. TURBT provides immediate tumour removal with minimal invasiveness, allowing quick recovery and return to daily activities. The procedure’s diagnostic value ensures accurate staging and appropriate risk stratification for tailored treatment planning.

Intravesical therapy substantially reduces recurrence rates, with BCG immunotherapy decreasing recurrence by up to 40% in high-risk cases. This localised treatment minimises systemic side effects compared to intravenous chemotherapy. Regular surveillance enables early detection of recurrences when they remain most treatable. The comprehensive treatment approach reduces progression risk to muscle-invasive disease, which would require more aggressive intervention. Many patients maintain good quality of life with preserved bladder function throughout long-term follow-up.

Common Side Effects

Temporary blood in urine (haematuria) affects most patients following TURBT, typically resolving within days. Urinary frequency and urgency commonly occur, particularly during intravesical therapy courses. Mild bladder irritation causing discomfort during urination usually improves with symptomatic management. BCG therapy frequently causes flu-like symptoms including low-grade fever, fatigue, and malaise lasting 1-2 days. Local inflammatory reactions from intravesical agents may cause temporary bladder capacity reduction.

Rare Complications

Bladder perforation during TURBT occurs in less than 5% of cases, usually managed conservatively with catheter drainage. Significant bleeding requiring transfusion remains uncommon with modern techniques. Urinary tract infections despite antibiotic prophylaxis may occasionally develop. BCG sepsis represents a rare but serious complication requiring immediate treatment. Allergic reactions to intravesical agents occasionally necessitate treatment modification. Urethral stricture development may occur with repeated procedures.

Risk minimisation occurs through careful surgical technique, appropriate patient selection, and experienced surgical teams. MOH-accredited urologists employ established protocols and safety measures to reduce complication likelihood. Prompt recognition and management of complications when they occur ensures positive outcomes.

Treatment costs for NMIBC vary based on tumour extent, number of lesions, and risk category determining follow-up intensity. Initial TURBT costs encompass surgical fees, anaesthesia, operating theatre charges, and hospitalisation. Pathology examination and special staining techniques add to diagnostic expenses. Intravesical therapy costs depend on the specific agent chosen and treatment duration, with BCG and chemotherapy agents having different price points.

Long-term surveillance represents a significant cost component, with regular cystoscopies, urine tests, and occasional imaging studies. Enhanced cystoscopy techniques using blue light or NBI may incur additional charges. The comprehensive treatment package typically includes surgeon consultations, nursing care, and medication management. Quality care from experienced MOH-accredited urologists provides value through improved outcomes and potentially fewer recurrences requiring intervention. Patients should discuss treatment costs during consultation for a personalised estimate based on their specific situation.